8-K: MIRA Pharmaceuticals Secures FDA IND Clearance for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Ketamir-2, enabling U.S.-based clinical trials for neuropathic pain.

Summary

• The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Ketamir-2, MIRA Pharmaceuticals' novel oral NMDA receptor antagonist for neuropathic pain.
• This clearance enables MIRA Pharmaceuticals to initiate U.S.-based clinical trials for Ketamir-2.
• Preclinical data for Ketamir-2 demonstrated potent analgesic effects and a favorable safety profile across validated models of diabetic, chemotherapy-induced, and nerve ligation-associated neuropathy.
• Ketamir-2 showed superior efficacy to gabapentin and pregabalin in head-to-head studies and no evidence of ketamine-associated neurotoxicity, along with good oral bioavailability and efficient blood-brain barrier penetration.
• Preclinical studies further indicated antidepressantand anxiolytic-like effects with no dissociative or psychotomimetic side effects.
• The company is nearing completion of the single ascending dose (SAD) portion of its international Phase 1 trial and is preparing to initiate the multiple ascending dose (MAD) portion.
• MIRA Pharmaceuticals plans to initiate its U.S.-based Phase 2a efficacy trial in the fourth quarter of 2025.
• MIRA continues to advance two other key programs: the planned acquisition of SKNY Pharmaceuticals, Inc. remains on track, with SKNY-1 showing robust preclinical efficacy in obesity and nicotine craving models, and MIRA-55, an oral cannabinoid analog, has demonstrated comparable efficacy to morphine in inflammatory pain models.

Sentiment

Score: 8

Explanation: The FDA IND clearance is a major positive catalyst, validating the drug candidate and enabling progression to human trials in a large market. Strong preclinical data and pipeline diversification further enhance positive sentiment.

Positives

• FDA IND clearance for Ketamir-2 is a significant regulatory milestone, enabling the initiation of U.S.-based clinical trials for neuropathic pain.
• Preclinical data for Ketamir-2 demonstrated superior efficacy compared to gabapentin and pregabalin in head-to-head studies.
• Ketamir-2 exhibited a favorable safety profile with no evidence of ketamine-associated neurotoxicity and no dissociative or psychotomimetic side effects.
• The drug candidate showed good oral bioavailability and efficient blood-brain barrier penetration.
• Ketamir-2 also demonstrated promising antidepressantand anxiolytic-like effects in preclinical studies.
• The planned acquisition of SKNY Pharmaceuticals, Inc. is on track, adding SKNY-1 with robust preclinical efficacy in obesity and nicotine craving models.
• MIRA-55, an oral cannabinoid analog, demonstrated comparable efficacy to morphine in inflammatory pain models, indicating potential as a potent non-opioid alternative.

Future Outlook

MIRA Pharmaceuticals plans to initiate its U.S.-based Phase 2a efficacy trial for Ketamir-2 in the fourth quarter of 2025. The planned acquisition of SKNY Pharmaceuticals, Inc. remains on track, and MIRA continues to evaluate MIRA-55 for further development.

Management Comments

• The FDA clearance of our IND for Ketamir-2 enables us to initiate U.S.-based clinical trials.

Industry Context

The FDA IND clearance for Ketamir-2 positions MIRA Pharmaceuticals as a potential innovator in the neuropathic pain market, a significant area of unmet medical need, particularly given the ongoing opioid crisis. Developing a non-opioid alternative with superior efficacy to existing treatments like gabapentin and pregabalin could be a major breakthrough, aligning with broader industry trends towards safer and more effective pain management solutions. The advancement of SKNY-1 for obesity and nicotine craving also taps into large, growing markets.

Comparison to Industry Standards

• Ketamir-2 demonstrated superior efficacy to gabapentin and pregabalin in head-to-head preclinical studies, indicating a potentially more effective treatment option compared to current standard-of-care non-opioid neuropathic pain medications.
• MIRA-55 showed comparable efficacy to morphine in inflammatory pain models, suggesting it could be a potent non-opioid alternative for pain management, similar to how other companies are exploring cannabinoid-based therapies.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress in drug development, potential for future value creation from successful clinical trials and pipeline expansion.
• Patients: Potential for a new, more effective, and safer non-opioid treatment option for neuropathic pain, and potentially for obesity, nicotine craving, and inflammatory pain.
• Healthcare Providers: New therapeutic options for challenging conditions.
• Employees: Continued job security and potential for growth as the company advances its pipeline.

Next Steps

• Complete the single ascending dose (SAD) portion of the international Phase 1 trial for Ketamir-2.
• Initiate the multiple ascending dose (MAD) portion of the international Phase 1 trial for Ketamir-2.
• Initiate U.S.-based Phase 2a efficacy trial for Ketamir-2 in Q4 2025.
• Continue with the planned acquisition of SKNY Pharmaceuticals, Inc.
• Further evaluate MIRA-55 for development.

Key Dates

Recommendation

The FDA IND clearance for Ketamir-2 is a critical de-risking event for MIRA Pharmaceuticals, allowing the company to advance its lead candidate into U.S. clinical trials for a large and underserved market (neuropathic pain). The preclinical data showing superior efficacy to existing treatments and a favorable safety profile is highly compelling. The planned initiation of a Phase 2a trial by year-end, coupled with progress on other promising pipeline assets (SKNY-1 and MIRA-55), indicates strong operational momentum and diversification. This news significantly enhances the company's long-term value proposition and reduces regulatory uncertainty, making it a strong buy for investors seeking exposure to innovative pharmaceutical development.

Keywords

MIRA Pharmaceuticals, Ketamir-2, FDA, IND clearance, neuropathic pain, clinical trials, NMDA receptor antagonist, pain management, pharmaceuticals, biotechnology, drug development, Phase 1, Phase 2a, SKNY Pharmaceuticals, MIRA-55, opioid alternative